Xiao Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiao Zheng has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jingting Jiang
Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Jiangsu Changzhou, China
4 shared publications - Lujun Chen
Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, China
4 shared publications - Jun Feng
Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China
3 shared publications - You Zhou
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003 Jiangsu China
3 shared publications - Bin Xu
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of China
2 shared publications - Jingting Jiang
Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, China
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in BMC Cancer
Evaluation of HHLA2 expression predicts poor survival in patients with esophageal squamous cell carcinoma
Background/Aims: Esophageal squamous cell carcinoma (ESCC) remains a major health burden in China, and the clinical benefit of immunotherapy is limited by the lack of reliable predictive biomarkers. Human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2), a recently identified immune checkpoint molecule of the B7 family, has been implicated in tumor immune evasion and disease progression across multiple malignancies. Therefore, this study investigated the expression pattern and prognostic significance of HHLA2 in ESCC. Methods: Multiplex immunofluorescence staining for HHLA2, CD68, and CD8 was performed on an ESCC tissue microarray to characterize HHLA2 expression within the tumor microenvironment (TME). Quantitative analyses were subsequently conducted to evaluate its associations with clinicopathological features and patient survival. Results: HHLA2 expression was significantly elevated in ESCC tissues compared with normal esophageal tissues. Patients with high HHLA2 expression exhibited significantly poorer overall survival (OS) than those with low expression in CK + tumor area and CK - stroma area. The combined analyses of HHLA2 expression and infiltration levels of CD8 + , CD68 + provided novel exploratory risk stratification biomarkers for ESCC patients. Increased HHLA2 expression on both CD68⁺tumor-associated macrophages (TAMs) and CD8⁺T-cells were likewise associated with unfavorable prognosis. Moreover, univariate and multivariate analyses both revealed that HHLA2 could served as an independent prognostic biomarker in esophageal cancer patients. Conclusion: HHLA2 was frequently overexpressed in ESCC and was associated with adverse clinical outcomes. The combination of HHLA2 expression and immune cell CD8 + , CD68 + infiltration levels could offer enhanced exploratory risk stratification biomarkers. These findings identified HHLA2 as a promising prognostic biomarker and a potential target for immunotherapeutic intervention in ESCC.
- 10 November 2026
- Published by Springer Nature in BMC Cancer
Open AccessEvaluation of HHLA2 expression predicts poor survival in patients with esophageal squamous cell carcinoma
Background/Aims: Esophageal squamous cell carcinoma (ESCC) remains a major health burden in China, and the clinical benefit of immunotherapy is limited by the lack of reliable predictive biomarkers. Human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2), a recently identified immune checkpoint molecule of the B7 family, has been implicated in tumor immune evasion and disease progression across multiple malignancies. Therefore, this study investigated the expression pattern and prognostic significance of HHLA2 in ESCC. Methods: Multiplex immunofluorescence staining for HHLA2, CD68, and CD8 was performed on an ESCC tissue microarray to characterize HHLA2 expression within the tumor microenvironment (TME). Quantitative analyses were subsequently conducted to evaluate its associations with clinicopathological features and patient survival. Results: HHLA2 expression was significantly elevated in ESCC tissues compared with normal esophageal tissues. Patients with high HHLA2 expression exhibited significantly poorer overall survival (OS) than those with low expression in CK + tumor area and CK - stroma area. The combined analyses of HHLA2 expression and infiltration levels of CD8 + , CD68 + provided novel exploratory risk stratification biomarkers for ESCC patients. Increased HHLA2 expression on both CD68⁺tumor-associated macrophages (TAMs) and CD8⁺T-cells were likewise associated with unfavorable prognosis. Moreover, univariate and multivariate analyses both revealed that HHLA2 could served as an independent prognostic biomarker in esophageal cancer patients. Conclusion: HHLA2 was frequently overexpressed in ESCC and was associated with adverse clinical outcomes. The combination of HHLA2 expression and immune cell CD8 + , CD68 + infiltration levels could offer enhanced exploratory risk stratification biomarkers. These findings identified HHLA2 as a promising prognostic biomarker and a potential target for immunotherapeutic intervention in ESCC.
- Open Access
- 3 July 2024
- Published by Springer Nature in Apoptosis
- Vol. 29 (11-12) , 1959-1977
Targeted delivery of FAK siRNA by engineered exosomes to reverse cetuximab resistance via activating paraptosis in colon cancer
Background: Cetuximab is extensively used in the treatment of metastatic colorectal cancer (mCRC). However, resistance poses a significant challenge to successful therapy. Recently, paraptosis, a non-classical programmed cell death, has garnered increased attention for its potential application value in antitumor treatments. We aimed to identify the essential pathways and signaling molecules involved in paraptosis inhibition and select them as therapeutic targets in cetuximab resistance. Additionally, engineered exosome technology is used as a drug delivery system with both targeted and effector properties. Results: By comparing the differential expression of paraptosis-related genes between drug-resistant colon cancer cells and sensitive cells, it was observed that the paraptosis level induced by cetuximab was significantly downregulated in drug-resistant cells. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis identified the focal adhesion kinase (FAK) signaling pathway as a key pathway involved in the suppression of paraptosis. The biological function of FAK in cetuximab-resistant cells was investigated through cell morphology observation, CCK-8 assay, colony formation assay, RT-qPCR, Western Blot, and loss-of-function experiments. The results showed that the FAK signaling pathway was significantly upregulated in cetuximab-resistant colon cancer cells, and siRNA interference targeting FAK could notably inhibit cell proliferation while upregulating the paraptosis level. Based on this, engineered colon cancer cells targeted and FAK siRNA loaded exosomes (CT-Exo-siFAK1) were constructed. In vitro experiments, CT-Exo-siFAK1 could effectively activate paraptosis and inhibit the proliferation of drug-resistant colon cancer cells. In vivo experiments also confirmed that CT-Exo-siFAK1 significantly suppressed tumor growth and metastasis while upregulating the paraptosis level. Conclusion: This study suggests that FAK signaling pathway-mediated inhibition of paraptosis levels is crucial in the sensitivity of cetuximab targeted therapy in colon cancer, and the use of engineered exosomes to deliver FAK siRNA may be an effective strategy to reverse cetuximab resistance.
- 3 July 2024
- Published by Springer Nature in Apoptosis
- Vol. 29 (11-12) , 1959-1977
Open AccessTargeted delivery of FAK siRNA by engineered exosomes to reverse cetuximab resistance via activating paraptosis in colon cancer
Background: Cetuximab is extensively used in the treatment of metastatic colorectal cancer (mCRC). However, resistance poses a significant challenge to successful therapy. Recently, paraptosis, a non-classical programmed cell death, has garnered increased attention for its potential application value in antitumor treatments. We aimed to identify the essential pathways and signaling molecules involved in paraptosis inhibition and select them as therapeutic targets in cetuximab resistance. Additionally, engineered exosome technology is used as a drug delivery system with both targeted and effector properties. Results: By comparing the differential expression of paraptosis-related genes between drug-resistant colon cancer cells and sensitive cells, it was observed that the paraptosis level induced by cetuximab was significantly downregulated in drug-resistant cells. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis identified the focal adhesion kinase (FAK) signaling pathway as a key pathway involved in the suppression of paraptosis. The biological function of FAK in cetuximab-resistant cells was investigated through cell morphology observation, CCK-8 assay, colony formation assay, RT-qPCR, Western Blot, and loss-of-function experiments. The results showed that the FAK signaling pathway was significantly upregulated in cetuximab-resistant colon cancer cells, and siRNA interference targeting FAK could notably inhibit cell proliferation while upregulating the paraptosis level. Based on this, engineered colon cancer cells targeted and FAK siRNA loaded exosomes (CT-Exo-siFAK1) were constructed. In vitro experiments, CT-Exo-siFAK1 could effectively activate paraptosis and inhibit the proliferation of drug-resistant colon cancer cells. In vivo experiments also confirmed that CT-Exo-siFAK1 significantly suppressed tumor growth and metastasis while upregulating the paraptosis level. Conclusion: This study suggests that FAK signaling pathway-mediated inhibition of paraptosis levels is crucial in the sensitivity of cetuximab targeted therapy in colon cancer, and the use of engineered exosomes to deliver FAK siRNA may be an effective strategy to reverse cetuximab resistance.
- Open Access
- 2 February 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 24 (5) , 927-940
STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer
Background: We have previously reported significant change of epithelial to mesenchymal transition (EMT) phenotype of Eca-109 cells upon PD-L1 operation, and the cytoplasmic domain of PD-L1 played an essential role in promoting EMT of esophageal cancer cells. However, the underlying mechanism of how PD-L1 regulated EMT in esophageal cancer remained unclear. Methods: The overexpression and knockdown expression models of PD-L1 and IFIT2 were established by using lenti-virus transfection and RNAi method. Western blotting, qRT-PCR, CCK8 assay, transwell assay and wound healing assay were chosen to investigate their impact on the cells. The expression levels of IFIT2 and EMT markers in esophageal cancer tissues were examined by immunohistochemical staining. The rescue experiments were further applied to investigate the role of STAT1/IFIT2 signal pathway in the PD-L1-mediated EMT. Luciferase reporter assays were performed to examine the IFIT2 promoter activities upon knockdown expression of PD-L1 to identify the putative targeted region of IFIT2 promoter. Results: The STAT1/IFIT2 signal pathway was activated when PD-L1 was knockdown in human esophageal cancer cells. Decreased IFIT2 expression significantly increased the cellular abilities of viability, invasion and migration by using RNAi method in human esophageal cancer cells. Decreased IFIT2 expression in esophageal cancer tissues significantly correlated with EMT status, and could be used as an independent prognostic predictor for the patients. Rescue experiments in PD-L1 knockdown cells further confirmed that STAT1/IFIT2 pathway was involved in the PD-L1 mediated EMT of esophageal cancer cells. Moreover, the luciferase reporter assay also confirmed that in esophageal cancer cells, the promoter region of IFIT2 (-3K~-1K) remains more active in PD-L1 knockdown expression cells compared with controls. Conclusion: Our present work reveals a novel mechanism of how PD-L1 regulates EMT of cancer cells, namely STAT1/IFIT2 signal pathway is required in PD-L1 mediated EMT in human esophageal cancer.
- 2 February 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 24 (5) , 927-940
Open AccessSTAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer
Background: We have previously reported significant change of epithelial to mesenchymal transition (EMT) phenotype of Eca-109 cells upon PD-L1 operation, and the cytoplasmic domain of PD-L1 played an essential role in promoting EMT of esophageal cancer cells. However, the underlying mechanism of how PD-L1 regulated EMT in esophageal cancer remained unclear. Methods: The overexpression and knockdown expression models of PD-L1 and IFIT2 were established by using lenti-virus transfection and RNAi method. Western blotting, qRT-PCR, CCK8 assay, transwell assay and wound healing assay were chosen to investigate their impact on the cells. The expression levels of IFIT2 and EMT markers in esophageal cancer tissues were examined by immunohistochemical staining. The rescue experiments were further applied to investigate the role of STAT1/IFIT2 signal pathway in the PD-L1-mediated EMT. Luciferase reporter assays were performed to examine the IFIT2 promoter activities upon knockdown expression of PD-L1 to identify the putative targeted region of IFIT2 promoter. Results: The STAT1/IFIT2 signal pathway was activated when PD-L1 was knockdown in human esophageal cancer cells. Decreased IFIT2 expression significantly increased the cellular abilities of viability, invasion and migration by using RNAi method in human esophageal cancer cells. Decreased IFIT2 expression in esophageal cancer tissues significantly correlated with EMT status, and could be used as an independent prognostic predictor for the patients. Rescue experiments in PD-L1 knockdown cells further confirmed that STAT1/IFIT2 pathway was involved in the PD-L1 mediated EMT of esophageal cancer cells. Moreover, the luciferase reporter assay also confirmed that in esophageal cancer cells, the promoter region of IFIT2 (-3K~-1K) remains more active in PD-L1 knockdown expression cells compared with controls. Conclusion: Our present work reveals a novel mechanism of how PD-L1 regulates EMT of cancer cells, namely STAT1/IFIT2 signal pathway is required in PD-L1 mediated EMT in human esophageal cancer.
- Retracted
- 21 January 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (10) , 6536-6547
Retracted: LINC00449 regulates the proliferation and invasion of acute monocytic leukemia and predicts favorable prognosis
Acute myeloid leukemia (AML) is a highly aggressive disease that causes high mortality. Long noncoding RNA (lncRNA) have studied in recent years that could be a potential biomarker and therapeutic target. Therefore, it is urgently necessary to explore the novel lncRNAs in AML. Microarray analysis was performed to determine the differentially expressed lncRNAs between mononuclear cells of AML and normal samples. The biological function of lncRNA on cell proliferation and migration was measured in vitro. The predicted downstream target of lncRNA was validated by dual‐luciferase reporter assay, RNA immunoprecipitation, RNA pull‐down, and rescue experiments. The tumor formation and metastasis study were conducted in vivo. The expression of lncRNA in clinical samples was determined by a quantitative reverse transcription‐polymerase chain reaction. LINC00449 was one of the most differentially expressed lncRNA which is mainly located in the cytoplasm. We found that overexpression of LINC00449 could inhibit the cell proliferation and invasion of AML cells in vitro and in vivo. Besides, miR‐150 was identified as the downstream target gene that was negatively regulated by LINC00449 and FOXD3 was targeted by miR‐150. The results were confirmed by dual‐luciferase reporter assay, RNA immunoprecipitation, RNA pull‐down, rescue experiments, and in vivo assays. Patients with AML with high expression of LINC0049 may characterize a favorable survival. All the above‐mentioned findings indicated that the LINC00449/miR‐150/FOXD3 signaling pathway might represent a novel prognostic biomarker or therapeutic target for the treatment of AML.
- 21 January 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (10) , 6536-6547
RetractedRetracted: LINC00449 regulates the proliferation and invasion of acute monocytic leukemia and predicts favorable prognosis
Acute myeloid leukemia (AML) is a highly aggressive disease that causes high mortality. Long noncoding RNA (lncRNA) have studied in recent years that could be a potential biomarker and therapeutic target. Therefore, it is urgently necessary to explore the novel lncRNAs in AML. Microarray analysis was performed to determine the differentially expressed lncRNAs between mononuclear cells of AML and normal samples. The biological function of lncRNA on cell proliferation and migration was measured in vitro. The predicted downstream target of lncRNA was validated by dual‐luciferase reporter assay, RNA immunoprecipitation, RNA pull‐down, and rescue experiments. The tumor formation and metastasis study were conducted in vivo. The expression of lncRNA in clinical samples was determined by a quantitative reverse transcription‐polymerase chain reaction. LINC00449 was one of the most differentially expressed lncRNA which is mainly located in the cytoplasm. We found that overexpression of LINC00449 could inhibit the cell proliferation and invasion of AML cells in vitro and in vivo. Besides, miR‐150 was identified as the downstream target gene that was negatively regulated by LINC00449 and FOXD3 was targeted by miR‐150. The results were confirmed by dual‐luciferase reporter assay, RNA immunoprecipitation, RNA pull‐down, rescue experiments, and in vivo assays. Patients with AML with high expression of LINC0049 may characterize a favorable survival. All the above‐mentioned findings indicated that the LINC00449/miR‐150/FOXD3 signaling pathway might represent a novel prognostic biomarker or therapeutic target for the treatment of AML.
- Open Access
- 28 May 2019
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 17 (1) , 178
Prognostic value of TIM-1 expression in human non-small-cell lung cancer
T-cell immunoglobulin and mucin domain 1 (TIM-1) is an important co-stimulatory molecule which serves as a surface marker for T cell activation, especially for Th2 cells. Recently, many studies have also shown that TIM-1 can be abnormally expressed in human cancers and may have a potential role in promoting cancer progression. The immunohistochemistry was used to examine the TIM-1 expression in human non-small-cell lung carcinoma (NSCLC) tissues. The cellular studies were performed to investigate the role of TIM-1 in the regulation of biological functions of human lung cancer cell lines. We found that the TIM-1 expression was increased in human NSCLC tissues compared with the adjacent normal tissues, and the OS rate of NSCLC patients with higher TIM-1 expression was significantly lower compared with the ones with lower TIM-1 expression. The COX model showed that higher TIM-1 expression in lung cancer tissues could be used as an independent prognostic predictor for the patients. Furthermore, we depleted TIM-1 in NSCLC cell lines A549 and SK-MES-1, and the cellular functional studies also revealed that depletion of TIM-1 could significantly inhibit the cell viability as well as the abilities of migration and invasion. In addition, our microarray data showed that certain signaling pathways were altered and enriched after depletion of TIM-1. We subsequently verified that PI3K/Akt signaling pathway was involved in the TIM-1-mediated regulation of cellular functions in NSCLC cells. Our findings supported the notion that TIM-1 could serve as a potential therapeutic target for NSCLC.
- 28 May 2019
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 17 (1) , 178
Open AccessPrognostic value of TIM-1 expression in human non-small-cell lung cancer
T-cell immunoglobulin and mucin domain 1 (TIM-1) is an important co-stimulatory molecule which serves as a surface marker for T cell activation, especially for Th2 cells. Recently, many studies have also shown that TIM-1 can be abnormally expressed in human cancers and may have a potential role in promoting cancer progression. The immunohistochemistry was used to examine the TIM-1 expression in human non-small-cell lung carcinoma (NSCLC) tissues. The cellular studies were performed to investigate the role of TIM-1 in the regulation of biological functions of human lung cancer cell lines. We found that the TIM-1 expression was increased in human NSCLC tissues compared with the adjacent normal tissues, and the OS rate of NSCLC patients with higher TIM-1 expression was significantly lower compared with the ones with lower TIM-1 expression. The COX model showed that higher TIM-1 expression in lung cancer tissues could be used as an independent prognostic predictor for the patients. Furthermore, we depleted TIM-1 in NSCLC cell lines A549 and SK-MES-1, and the cellular functional studies also revealed that depletion of TIM-1 could significantly inhibit the cell viability as well as the abilities of migration and invasion. In addition, our microarray data showed that certain signaling pathways were altered and enriched after depletion of TIM-1. We subsequently verified that PI3K/Akt signaling pathway was involved in the TIM-1-mediated regulation of cellular functions in NSCLC cells. Our findings supported the notion that TIM-1 could serve as a potential therapeutic target for NSCLC.
- Open Access
- 1 February 2019
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 67 (2) , 331-337
Nomogram incorporating clinicopathological parameters to predict the survival of patients with mantle cell lymphoma
This study intended to present a practicable prognostic nomogram for patients with mantle cell lymphoma (MCL). The clinical data of 281 patients were reviewed. A nomogram that could predict overall survival (OS) was constructed based on the Cox proportional hazard model. To compare the capacity of the nomogram with the International Prognostic Index (IPI) and MCL International Prognostic Index (MIPI) scoring systems, we used the concordance index (C-index) to validate the veracity and the calibration curve. Age, Eastern Cooperation Oncology Group, lactate dehydrogenase, white cell count and Ki-67 were independent prognostic factors in the multivariate analysis and were subsequently included in the nomogram construction. The C-index was 0.81 and 0.79 in the primary and validation cohorts, respectively, which were superior to the predictive capacity of the IPI and MIPI systems in both cohorts. The nomogram makes it possible for physicians to predict patient OS individually and correctly, but certain limitations are noted.
- 1 February 2019
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 67 (2) , 331-337
Open AccessNomogram incorporating clinicopathological parameters to predict the survival of patients with mantle cell lymphoma
This study intended to present a practicable prognostic nomogram for patients with mantle cell lymphoma (MCL). The clinical data of 281 patients were reviewed. A nomogram that could predict overall survival (OS) was constructed based on the Cox proportional hazard model. To compare the capacity of the nomogram with the International Prognostic Index (IPI) and MCL International Prognostic Index (MIPI) scoring systems, we used the concordance index (C-index) to validate the veracity and the calibration curve. Age, Eastern Cooperation Oncology Group, lactate dehydrogenase, white cell count and Ki-67 were independent prognostic factors in the multivariate analysis and were subsequently included in the nomogram construction. The C-index was 0.81 and 0.79 in the primary and validation cohorts, respectively, which were superior to the predictive capacity of the IPI and MIPI systems in both cohorts. The nomogram makes it possible for physicians to predict patient OS individually and correctly, but certain limitations are noted.
- Open Access
- 4 September 2018
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 1-10
Expression of B7-H6 expression in human hepatocellular carcinoma and its clinical significance
Recent studies have suggested that B7-H6, a new member of the B7 family of ligands, not only is a crucial regulator of NK cell-mediated immune responses but also has important clinical implications due to its abnormal expression in many human cancers. We have previously reported that higher B7-H6 expression levels in ovarian cancer tissues are positively correlated with tumor metastasis and cancer progression. To date, the expression of B7-H6 in human hepatocellular carcinoma (HCC) and the clinical significance of B7-H6 expression still remain elusive. In the present study, the expression level of B7-H6 was examined in both HCC tissues and HCC cell lines (HepG2 and SMMC-7721). And the clinical significance of B7-H6 was analyzed as well. Our results revealed that B7-H6 was expressed abnormally in HCC tissues, which was greatly related to tumor size. The TCGA data also showed that the B7-H6 mRNA expression level was significantly negatively correlated with the survival of HCC patients. Next, to investigate the functions of B7-H6 in HCC, we successfully constructed B7-H6 knockdown expression human HCC cell lines using the RNA interference technology. Our studies showed that reduced expression of B7-H6 in HepG2 and SMMC-7721 cells significantly attenuated cell proliferation as well as cell migration and invasion. Besides, depletion of B7-H6 greatly induced cell cycle arrest at G1 phase. And also B7-H6 knockdown in HCC cell lines dramatically decreased the C-myc, C-fos and Cyclin-D1 expression. Our present findings suggested that B7-H6 played an important role in oncogenesis of HCC on cellular level, and B7-H6 could be employed to develop immunotherapeutic approaches targeting this malignancy.
- 4 September 2018
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 1-10
Open AccessExpression of B7-H6 expression in human hepatocellular carcinoma and its clinical significance
Recent studies have suggested that B7-H6, a new member of the B7 family of ligands, not only is a crucial regulator of NK cell-mediated immune responses but also has important clinical implications due to its abnormal expression in many human cancers. We have previously reported that higher B7-H6 expression levels in ovarian cancer tissues are positively correlated with tumor metastasis and cancer progression. To date, the expression of B7-H6 in human hepatocellular carcinoma (HCC) and the clinical significance of B7-H6 expression still remain elusive. In the present study, the expression level of B7-H6 was examined in both HCC tissues and HCC cell lines (HepG2 and SMMC-7721). And the clinical significance of B7-H6 was analyzed as well. Our results revealed that B7-H6 was expressed abnormally in HCC tissues, which was greatly related to tumor size. The TCGA data also showed that the B7-H6 mRNA expression level was significantly negatively correlated with the survival of HCC patients. Next, to investigate the functions of B7-H6 in HCC, we successfully constructed B7-H6 knockdown expression human HCC cell lines using the RNA interference technology. Our studies showed that reduced expression of B7-H6 in HepG2 and SMMC-7721 cells significantly attenuated cell proliferation as well as cell migration and invasion. Besides, depletion of B7-H6 greatly induced cell cycle arrest at G1 phase. And also B7-H6 knockdown in HCC cell lines dramatically decreased the C-myc, C-fos and Cyclin-D1 expression. Our present findings suggested that B7-H6 played an important role in oncogenesis of HCC on cellular level, and B7-H6 could be employed to develop immunotherapeutic approaches targeting this malignancy.
- Open Access
- 12 August 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 1-5
Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors
CIK cells therapy has been evaluated as an adoptive cell immunotherapy for cancer patients, but there still have not been any standardized systems for evaluating the antitumor efficacy yet. The WHO and RECIST criteria have already been established for a few years but not sufficient to fully characterize the activity of immunotherapy. Based on these two criteria, the irRC was proposed for evaluating the efficacy of immunotherapy. A variety of bioassays for immune monitoring including the specific and non-specific methods, have been established. We recommend detect levels of various immunocytes, immune molecules and soluble molecules to find the correlations among them and clinicopathological characteristics to establish criteria for immunological classification. We also recommend a paradigm shift for the oncologists in the evaluation of immune therapies to ensure assessment of activity based on clinically relevant criteria and time points.
- 12 August 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 1-5
Open AccessEvaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors
CIK cells therapy has been evaluated as an adoptive cell immunotherapy for cancer patients, but there still have not been any standardized systems for evaluating the antitumor efficacy yet. The WHO and RECIST criteria have already been established for a few years but not sufficient to fully characterize the activity of immunotherapy. Based on these two criteria, the irRC was proposed for evaluating the efficacy of immunotherapy. A variety of bioassays for immune monitoring including the specific and non-specific methods, have been established. We recommend detect levels of various immunocytes, immune molecules and soluble molecules to find the correlations among them and clinicopathological characteristics to establish criteria for immunological classification. We also recommend a paradigm shift for the oncologists in the evaluation of immune therapies to ensure assessment of activity based on clinically relevant criteria and time points.
- Open Access
- 19 June 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 1-5
Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer
B7-H4 is a novel B7 ligand that plays an important role in the T cell-mediated immune response as a negative regulator. Previous studies have suggested the aberrant expression of membrane B7-H4 in tumor cells. The aim of this study is to determine the expression levels of preoperative soluble B7-H4 (sB7-H4) in circulation and to investigate the correlations between sB7-H4 levels and clinicopathological parameters as well as the survival rate of patients with gastric cancer. Blood specimens from 132 patients with gastric cancer and 63 healthy volunteers were analyzed by sandwich enzyme-linked immunosorbent assay. Median concentrations of sB7-H4 in patients with gastric cancer were significantly higher than those in healthy volunteers (16.85 versus 10.46 ng/mL; P = 0.008). Median levels of sB7-H4 were significantly correlated with tumor size, lymph node metastasis, the depth of tumor invasion and tumor-node-metastasis classification (P = 0.002, P = 0.001, P = 0.041 and P 0.05). Additionally, the overall survival rate was significantly lower in patients with high sB7-H4 levels when compared with low sB7-H4 levels (50.0% versus 77.3%, χ2 = 10.78, P = 0.001). Moreover, multivariate analysis demonstrated that the risk of death was significantly higher in patients with high sB7-H4 levels than in those with low sB7-H4 levels (P = 0.039). sB7-H4 is a valuable blood marker for predicting the progression and prognosis of patients with gastric cancer.
- 19 June 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 1-5
Open AccessSerum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer
B7-H4 is a novel B7 ligand that plays an important role in the T cell-mediated immune response as a negative regulator. Previous studies have suggested the aberrant expression of membrane B7-H4 in tumor cells. The aim of this study is to determine the expression levels of preoperative soluble B7-H4 (sB7-H4) in circulation and to investigate the correlations between sB7-H4 levels and clinicopathological parameters as well as the survival rate of patients with gastric cancer. Blood specimens from 132 patients with gastric cancer and 63 healthy volunteers were analyzed by sandwich enzyme-linked immunosorbent assay. Median concentrations of sB7-H4 in patients with gastric cancer were significantly higher than those in healthy volunteers (16.85 versus 10.46 ng/mL; P = 0.008). Median levels of sB7-H4 were significantly correlated with tumor size, lymph node metastasis, the depth of tumor invasion and tumor-node-metastasis classification (P = 0.002, P = 0.001, P = 0.041 and P 0.05). Additionally, the overall survival rate was significantly lower in patients with high sB7-H4 levels when compared with low sB7-H4 levels (50.0% versus 77.3%, χ2 = 10.78, P = 0.001). Moreover, multivariate analysis demonstrated that the risk of death was significantly higher in patients with high sB7-H4 levels than in those with low sB7-H4 levels (P = 0.039). sB7-H4 is a valuable blood marker for predicting the progression and prognosis of patients with gastric cancer.